Related Experiment Videos
Characterization of tumor-associated Chk2 mutations
1Guggenheim 1342, Division of Oncology Research, Mayo Clinic, Rochester, Minnesota 55905, USA.
Abstract:
The integrity of the DNA damage response pathway is essential for prevention of neoplastic transformation. Several proteins involved in this pathway including p53, BRCA1, and ATM are frequently mutated in human cancer. Checkpoint kinase 2 (Chk2) is a DNA damage-activated protein kinase that lies downstream of ATM in this pathway. Recently, heterozygous germline mutations in Chk2 have been identified in a subset of patients with Li-Fraumeni syndrome, a highly penetrant familial cancer phenotype, suggesting that Chk2 is a tumor suppressor gene. In this study, we have reported the biochemical characterization of the four tumor-associated Chk2 mutants. Two of the reported Chk2 mutations identified in Li-Fraumeni syndrome result in loss of Chk2 kinase activity. Whereas one mutation within the Chk2 forkhead homology-associated (FHA) domain, R145W, retains some basal kinase activity, this mutant cannot be phosphorylated at an ATM-dependent phosphorylation site (Thr-68) and cannot be activated following gamma radiation. Wild-type Chk2 exists mainly in a protein complex of M(r) approximately 200,000 whereas the R145W mutant forms a larger, presumably inactive complex in the cell. The other FHA domain mutant, I157T, behaves as wild-type Chk2 in all the assays used here. Because the FHA domain is involved in protein-protein interactions, this mutation may affect associations of Chk2 with other proteins. Additionally, we have shown that Chk2 can also be inactivated by down-regulation of its expression in cancer cells. Thus, Chk2 may be inactivated by multiple mechanisms in the cell.
Insights
Checkpoint kinase 2 (Chk2) mutations, identified in Li-Fraumeni syndrome, can impair its tumor suppressor function. Some Chk2 mutants lose kinase activity or fail to activate, while others may affect protein interactions, contributing to cancer development.
Area of Science:
- Molecular Biology
- Cancer Genetics
- Biochemistry
Background:
- The DNA damage response (DDR) pathway is crucial for preventing cancer.
- Mutations in DDR proteins like p53, BRCA1, and ATM are common in human cancers.
- Checkpoint kinase 2 (Chk2) is a key kinase in the DDR pathway, activated by ATM.
Purpose of the Study:
- To biochemically characterize tumor-associated Chk2 mutants.
- To investigate the functional impact of Li-Fraumeni syndrome-associated Chk2 mutations.
- To explore mechanisms of Chk2 inactivation in cancer.
Main Methods:
- Biochemical assays to assess Chk2 kinase activity.
- Analysis of Chk2 protein complex formation.
- Examination of Chk2 phosphorylation and activation in response to DNA damage (gamma radiation).
Main Results:
- Two Li-Fraumeni syndrome Chk2 mutations resulted in loss of kinase activity.
- The R145W Chk2 mutant, within the FHA domain, showed reduced activation and altered complex formation.
- The I157T Chk2 mutant exhibited wild-type behavior in tested assays, suggesting potential effects on protein interactions.
- Chk2 expression downregulation was also observed in cancer cells.
Conclusions:
- Specific Chk2 mutations identified in Li-Fraumeni syndrome can inactivate its tumor suppressor function.
- Chk2 inactivation can occur through loss of kinase activity, impaired activation, altered protein complex formation, or reduced expression.
- These findings highlight the critical role of Chk2 integrity in preventing neoplastic transformation.